Vince Martin
View Vince Martin's Articles BY TICKER:
AAPL,
AE,
AEIS,
AEO,
AGX,
AMD,
AMZN,
ASCA,
ASYS,
ATVI,
AVX,
BBRY,
BCOR,
BRKS,
BSET,
CAT,
CATO,
CHK,
CONN,
COP,
CPIX,
CRAY,
CRM,
CZR,
DELL,
DISH,
DTLK,
DXBGY.PK,
EGY,
ENTR,
FRX,
FSII,
GENC,
GES,
GLD,
GLW,
GME,
GOOG,
GPS,
GROW,
HPQ,
IM,
INTC,
ISCA,
LEDS,
LMNX,
LOOK,
LTXC,
LUV,
LVS,
MDT,
MS,
MSN,
NFLX,
OPLK,
OVTI,
PBI,
PCCC,
PERI,
PG,
PIR,
PSSI,
PTNT,
RHT,
RSH,
RT,
SKS,
SMRT,
TC,
TIVO,
TRLG,
VOXX,
XRT,
XRX,
ZNGA
- Cumberland Pharma On The Right Track... But Moving Slowly
-
Saks Rumors Make No Sense; Neither Does Its Share Price
-
Can Contract Manufacturers Continue Their Strong Bull Run?
-
Buy VOXX International - If You Can Stomach It
-
Blucora Should Still Have Room To Run
-
No News Is Good News For Thompson Creek
-
The Problems With Ackman's Thesis On Procter & Gamble
-
Sell The News On Stein Mart
-
Fade SemiLEDs' Stunning, Irrational Rally
-
Cato Has Become A Value Trap
-
Procter & Gamble Earnings Show Significant Challenges Ahead
- Where Internet Patents Corporation Stands Now
-
Guess? Outlook Should Cause Certain Worry
-
Be Wary Of Adams Resources' Big Run
-
Thompson Creek: Fundamentals Look Strong, But...
- CEO Loss Looks Bullish For True Religion
-
Pincus's Comments Belie Zynga's Poker Aspirations
-
Corning Looks More Than Fairly Valued
- The Effect Of A Netflix Price Hike
- Medtronic's Long-Term Plans Unaffected By Short-Term Worries
- What Is Activision Blizzard Planning?
- True Religion Still Worth A Look
-
Cumberland Pharmaceuticals: A Rare Value Stock In The Drug Industry
-
Caesars' Short Case Clearer, Simpler -- And Stronger
-
Perion's Risks Extend Beyond Bloomberg Report
- Intel's Full-Year Guidance Is Actually Very Good
-
Beware Argan's Tempting Balance Sheet
-
Update: A Buy, A Sell, And 2 Holds In The LED Sector
-
Gencor Is Cheap - For Good Reason
-
Ruby Tuesday's Real Estate Should Drive Its Turnaround
-
Why Doesn't Google Get The Amazon Treatment?
-
How Apple Gets To $400 A Share